Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
BULLISH SIGNAL DETECTED · Alpha
██.█% Sign up free to reveal

Dianthus Therapeutics, Inc. /De/ (DNTH) AI Forecast

Our AI ranks Dianthus Therapeutics, Inc. /De/ outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

✓ Free account • ✓ 30-day free trial

$DNTH Bullish Signal Full forecast available
Sign Up Free

Dianthus Therapeutics, Inc. /De/ (DNTH) Stock Forecast Sept. 24, 2026

Dianthus Therapeutics, Inc. /De/ (DNTH) AI Stock Price Forecast & Investment Analysis

Dianthus Therapeutics, Inc. /De/ Stock Price Chart and Technical Analysis

Loading chart...

Dianthus Therapeutics, Inc. /De/ (DNTH) - Comprehensive Stock Analysis & Investment Research

Deep dive into Dianthus Therapeutics, Inc. /De/'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on September 24, 2026 (UTC)

Dianthus Therapeutics, Inc. /De/ Investment Summary

When evaluating whether Dianthus Therapeutics, Inc. /De/ (DNTH) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Dianthus Therapeutics, Inc. /De/ (DNTH) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry. . With a market capitalization of $5 billion, the company is a mid-cap stock that typically offers a balance between growth potential and established business operations.

Financial Performance Analysis

Our comprehensive financial analysis covers Dianthus Therapeutics, Inc. /De/'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Dianthus Therapeutics, Inc. /De/ along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Dianthus Therapeutics, Inc. /De/ is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Dianthus Therapeutics, Inc. /De/

Sign Up Free
Corporate Identity

Dianthus Therapeutics, Inc. /De/ (Stock Symbol: DNTH) is a prominent company operating within the Life Sciences sector, with a specific focus on the Pharmaceutical Preparations industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Dianthus Therapeutics, Inc. /De/'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Dianthus Therapeutics, Inc. /De/...

Sector & Industry Analysis

In-depth sector dynamics and industry context for Dianthus Therapeutics, Inc. /De/...

Unlock Full Company Profile

Get complete details about Dianthus Therapeutics, Inc. /De/

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Dianthus Therapeutics, Inc. /De/...

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Dianthus Therapeutics, Inc. /De/...

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Dianthus Therapeutics, Inc. /De/...

Unlock Financial Analysis

Get complete financial metrics for Dianthus Therapeutics, Inc. /De/

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Dianthus Therapeutics, Inc. /De/'s AI Price Forecast

Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

4537 Stocks in the out-of-sample test
73.7% Rebalance periods with a positive net return
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Dianthus Therapeutics, Inc. /De/ strategically competes in the highly dynamic Pharmaceutical Preparations marketplace. As a mid-cap company, it occupies an attractive position balancing growth potential with established operations. Mid-caps often represent the 'sweet spot' for investors seeking companies that have proven their business models but still have meaningful runway for expansion. These companies are large enough to have competitive advantages but nimble enough to adapt quickly to market changes.

Industry Competitive Landscape

Dianthus Therapeutics, Inc. /De/ competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency
Financial Strength & Leverage

Current ratio of 26.10 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Dianthus Therapeutics, Inc. /De/ (DNTH) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Dianthus Therapeutics, Inc. /De/ stock analysis.

Deep dive into Dianthus Therapeutics, Inc. /De/'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Dianthus Therapeutics, Inc. /De/ stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Dianthus Therapeutics, Inc. /De/:

P/B Ratio 4.33x
Market Cap $5.07B
EPS $-4.22
Book Value/Share $20.95
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Dianthus Therapeutics, Inc. /De/ converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Dianthus Therapeutics, Inc. /De/: An ROE of -16.4% indicates room for improvement in shareholder value creation.

ROE -16.4%
ROA -15.9%
ROIC -18.5%
Operating Margin -18828.4%
Net Margin -16615.9%
EBT Margin -18828.4%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Dianthus Therapeutics, Inc. /De/'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Dianthus Therapeutics, Inc. /De/: A current ratio of 26.10 indicates strong liquidity.

Current Ratio 26.10x
D/E Ratio 0.04x
Financial Leverage 1.04x
Working Capital $863M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Dianthus Therapeutics, Inc. /De/'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Dianthus Therapeutics, Inc. /De/:

Operating Cash Flow -$155M
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Dianthus Therapeutics, Inc. /De/ uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Dianthus Therapeutics, Inc. /De/:

Understanding Financial Statement Data

What these metrics mean: Key figures from Dianthus Therapeutics, Inc. /De/'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Dianthus Therapeutics, Inc. /De/:

Income Statement
Operating Income -$217M
Net Income -$192M
R&D Expense $176M
Balance Sheet Highlights (USD millions)
Total Current Assets $898M (74.0% of assets)
Cash & Short-term Investments $111M (9.1% of assets)
Accounts Receivable $110K (0.0% of assets)
Total Liabilities $41M (3.4% of assets)
Short-term Debt $28M (2.3% of assets)
Dividend & Shareholder Information
Shares Outstanding 56M

Latest Dianthus Therapeutics, Inc. /De/ Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Dianthus Therapeutics, Inc. /De/ (DNTH) stock price and investment outlook.

📰 Loading...

Where DNTH sits on the market map

Explore the map →

Dianthus Therapeutics, Inc. /De/ Industry Peers - Pharmaceutical Preparations

Companies classified under the same SEC industry code as Dianthus Therapeutics, Inc. /De/ (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Company Ticker Symbol 90-Day AI Forecast (Alpha) Market Cap (USD M) P/E Ratio P/B Ratio
DNTH ██% $5.07B x 4.3x
LLY ██% $1.08T 40.6x 110.2x
JNJ ██% $648.67B 30.8x 7.6x
ONC ██% $539.52B x 104.3x
ABBV ██% $468.43B 74.2x x
MRK ██% $365.34B 115.1x 8.7x
NVS ██% $272.31B x x
GSK ██% $214.26B x x
ABT ██% $180.26B 28.6x 3.5x
PFE ██% $160.62B 37.1x 1.9x
VRTX ██% $130.87B 29.7x 6.5x
BMY ██% $125.63B 13.5x 5.6x
REGN ██% $82.55B 19.1x 2.6x
SNY ██% $50.80B x x
TEVA ██% $45.46B 64.3x 5.9x
ALNY ██% $33.40B x 24.7x
RPRX ██% $33.15B 40.7x 4.9x
ATHE ██% $32.40B x x
TAK ██% $29.93B x x
ZLAB ██% $29.68B x 48.9x
ZTS ██% $29.59B 11.3x 9.4x
ROIV ██% $26.60B x 6.3x
INSM ██% $25.84B x 34.1x
UTHR ██% $20.99B 16.0x 3.3x
VTRS ██% $19.66B x x
JAZZ ██% $15.25B 16.2x 3.2x
ASND ██% $14.30B x x
SMMT ██% $13.12B x 20.8x
BBIO ██% $12.96B x x
CORT ██% $12.81B x 18.2x
HCM ██% $12.54B x 10.1x
BMRN ██% $11.88B x 1.9x
KNSA ██% $11.87B x 19.6x
MDGL ██% $11.85B x 22.6x
ELAN ██% $11.17B x 1.7x
RDY ██% $10.34B x x
AXSM ██% $10.27B x 123.3x
ARWR ██% $9.33B x 20.1x
CYTK ██% $9.13B x x
PTGX ██% $8.98B x 10.7x
PRAX ██% $7.88B x 5.9x
SYRE ██% $7.77B x 7.1x
GPCR ██% $7.71B x 5.7x
ABVX ██% $7.39B x x
IONS ██% $7.30B x 16.6x
ALKS ██% $6.84B x 3.8x
LEGN ██% $6.82B x x
RYTM ██% $6.76B x 65.7x
BLRX ██% $6.68B x x
BLTE ██% $6.67B x 8.7x
AMRX ██% $6.32B x x
LQDA ██% $6.04B x 31.0x
LGND ██% $5.95B 30.2x 6.2x
MIRM ██% $5.80B x x
AMRN ██% $5.64B x 12.7x
TVTX ██% $5.64B x 230.0x
COGT ██% $5.45B x 10.2x
PTCT ██% $5.20B x x
ERAS ██% $5.08B x 14.0x
VKTX ██% $4.86B x 11.9x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Dianthus Therapeutics, Inc. /De/ Stock Forecast

How accurate are Dianthus Therapeutics, Inc. /De/ stock predictions?

A per-ticker accuracy statistic for DNTH is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

What factors influence Dianthus Therapeutics, Inc. /De/ stock price forecasts?

Our analysis considers Dianthus Therapeutics, Inc. /De/'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Dianthus Therapeutics, Inc. /De/ a good investment in 2026?

Based on our AI analysis, Dianthus Therapeutics, Inc. /De/ shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Dianthus Therapeutics, Inc. /De/ forecasts updated?

Dianthus Therapeutics, Inc. /De/ forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on September 24, 2026.

Want a simpler view of Dianthus Therapeutics, Inc. /De/?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...